T-cell receptor recognizing WT1-peptide-MHC complex (TCR recognizing WT1-peptide-MHC (or WT1 TCR; not a standardized abbreviation, but "TCR" is ubiquitous))

A **T-cell receptor (TCR) recognizing the WT1-peptide-MHC complex** is a heterodimeric, antigen-specific receptor on the surface of cytotoxic or helper T cells that binds specifically to a peptide derived from the Wilms Tumor 1 (WT1) protein, presented in the peptide-binding groove of a major histocompatibility complex (MHC) molecule, most often class I (e.g., HLA-A*02:01)[1][3][6][8]. This tripartite molecular recognition is a central event in adaptive immunity, enabling T cells to detect and respond to cancer cells overexpressing WT1—a tumor-associated antigen found frequently in leukemias and solid tumors[1][4][8]. Engineered TCRs with enhanced affinity for the WT1 peptide-MHC complex, as well as TCR-mimic antibodies and bispecific T cell engagers (e.g., WT1-TCB), have become promising modalities for targeted immunotherapy, but careful attention to specificity is required to avoid harmful autoimmunity due to off-target cross-reactivity or altered MHC/peptide binding properties[1][5][8]. WT1 mRNA levels and HLA typing are important for patient selection and therapy monitoring[8].

Other names

WT1-specific TCRTCR specific for WT1-peptide-HLA complexWT1 T-cell receptorT-cell receptor targeting WT1 peptide-MHC

Recognition of WT1 peptide bound to MHC class I on the surface of tumor cells triggers T-cell mediated cytotoxicity or immune-modulatory signaling[1][3][8]. TCR-mimic antibodies and bispecific antibodies cross-link T cells with WT1-presenting tumor cells to induce targeted cell killing[8].